Name: Clinical Pipeline - Aspen
Uploaded: 2022-01-13T11:12:38+00:00
Description: Our lead clinical development program is an autologous neuron replacement therapy for idiopathic Parkinson’s disease.

Our lead clinical development program is an autologous neuron replacement therapy for idiopathic Parkinson’s disease.

Our lead product (ANPD001) has received IND clearance and Fast Track designation from the U.S. Food and Drug Administration, and is currently under investigation in the Phase 1/2a ASPIRO trial for the treatment of sporadic Parkinson’s disease.

Our clinical development programs encompass multiple candidates for cell replacement therapy within the Central Nervous System (CNS). Our flagship candidate, ANPD001, is an autologous neuron replacement therapy in sporadic Parkinson’s disease (ANPD001).

We are also investigating several candidates for the treatment of both sporadic and genetic forms of Parkinson’s disease, as well as additional candidates targeted in the CNS.

Strong Pipeline Focused on Parkinson’s Disease

Additional opportunities to leverage platform with other cell types

Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson’s disease in a genomic era. Trends Genet. (2015) 31:140–9. 10.1016/j.tig.2015.01.004

Sidransky, Ellen, et al. “Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.” New England Journal of Medicine 361.17 (2009): 1651-1661.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.